Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCR5Δ32 cord blood stem cells
- Development stage
- Unknown
- Lead developer
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CCR5Δ32 cord blood stem cells refers to a therapeutic approach using umbilical cord blood-derived hematopoietic stem cells from donors who are homozygous for the CCR5Δ32 mutation. This cell therapy strategy is used to treat patients with HIV-1 and concurrent hematologic malignancies, such as acute myeloid leukemia, who require hematopoietic stem cell transplantation. The CCR5Δ32 mutation is a 32-base pair deletion in the CCR5 gene that results in a non-functional CCR5 co-receptor, which is the primary entry point for most HIV-1 strains into CD4+ T cells. By replacing the patient's immune system with these resistant cells, the therapy aims to achieve long-term HIV remission or a cure. Research has been led by institutions such as Weill Cornell Medicine and the IMPAACT network, utilizing cord blood units screened by banks like StemCyte.
- Other names
- CCR5-delta32 umbilical cord bloodCCR-5-delta32 umbilical cord bloodCCR 5-delta32 umbilical cord bloodCCR5Δ32/Δ32 cord bloodHIV-resistant cord blood stem cells
02
Targets
CCR5 (C-C chemokine receptor type 5)
Beyond the preview
Go deeper on CCR5Δ32 cord blood stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCR5Δ32 cord blood stem cells.